RhythmScience Announces Formation of Medical Advisory Board. Learn more
March 26, 2023
AI-Powered Cardiology Data Platform Uses Cloud-Based Software to Maximize Patient Care While Minimizing Clinical Workload
SAN FRANCISCO (March 24, 2023) – RhythmScience, a leader in cardiac data, today announces the close of its Series A funding led by Cedars-Sinai Health Ventures, with participation from new investor OCA Ventures and existing investor TenOneTenVentures.. The $6M investment will propel the development of the innovative Rhythm360 cardiology data platform that offers providers a complete data system across hypertension, heart failure, and rhythm disorders.
The Rhythm360 platform by RhythmScience digitally analyzes cardiac data from tens of thousands of patients across the U.S., including those in the University of Chicago Department of Medicine and the Methodist Debakey Heart Center at Houston Methodist health systems, and creates standardized data that reduce missed diagnoses and helps avoid unnecessary hospitalizations. Rhythm360 offers a single-source solution to track all cardiac implants and wearables, blood pressure cuffs and weight scales in one integrated portal.
“This is a very exciting opportunity for RhythmScience,” said Shawn Kumar, founder and CEO of RhythmScience. “We are grateful to be supported by a leading hospital with valuable industry resources and insights. Our collaboration with Cedars-Sinai Health Ventures will undoubtedly improve cardiology care through greater innovation and widespread implementation of our Rhythm360 AI-powered cardiology data platform.”
The funding and mentorship provided by Cedars-Sinai Health Ventures will help RhythmScience expand their footprint in the large market for cardiac data. The current monitoring solutions used by electrophysiologists, heart failure specialists and cardiologists often overlook important data points due to the abundance of information that must be reviewed. Rhythm360 alleviates the burden on clinical teams by providing an accessible and integrated monitoring system that analyzes data in a timely, efficient and clinically useful manner. By assisting nurses and clinical staff in evaluating large amounts of device data, Rhythm360 works to protect patients with chronic cardiac conditions from life-threatening complications.
Cedars-Sinai Medical Center, ranked the #2 hospital in the U.S. and the #1 hospital in California by U.S. News & World Report’s “Best Hospitals 2022-23” is home to the Smidt Heart Institute, ranked #1 for heart care in California.
Cedars-Sinai strives to continuously improve healthcare quality and efficiency by investing in health tech entrepreneurs through its venture arm, Cedars-Sinai Health Ventures. The investment in RhythmScience will help drive the cutting-edge technology of the Rhythm360(R) monitoring platform which has the potential of enhancing Cedars-Sinai’s mission of transforming healthcare delivery and patient care.
“We understand the need for effective cardiac data solutions that are purposefully built to meet the needs of patients and their cardiology teams,” said James Laur, managing director, Cedars-Sinai Health Ventures. “We believe that our collaboration with RhythmScience will further our leadership in the cardiac data space and provide our physicians with the best tools possible to prioritize the health and safety of our patients.”
RhythmScience was founded to solve the need of clinicians and doctors to unlock the power of cardiac data in improving heart health. RhythmScience is revolutionizing cardiac data by providing the building blocks for comprehensive cardiac care. Learn more about RhythmScience at https://www.rhythm360.io/.
